Dynavax Technologies reported $83.37M in Cost of Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
TG Therapeutics TGTX:US 23K 214K
Abbvie ABBV:US $ 4142M 121M
Adma Biologics ADMA:US $ 25.44M 2.57M
Amgen AMGN:US $ 1510M 51M
Astrazeneca AZN:US 1.9B 375M
AstraZeneca AZN:LN 1904M 375M
Biogen BIIB:US $ 484M 269.9M
Biomarin Pharmaceutical BMRN:US $ 123.13M 6.16M
Bristol Myers Squibb BMY:US $ 2677M 206M
Chimerix CMRX:US 0 114K
Dynavax Technologies DVAX:US $ 83.37M 43.41M
Gilead Sciences GILD:US $ 1442M 18M
Glaxosmithkline GSK:US $ 2136M 1509M
Merk MRK:US $ 3698M 1636M
Nektar Therapeutics NKTR:US $ 5.12M 0.2M
Neurocrine Biosciences NBIX:US $ 4.8M 0.2M
Novartis NOVN:VX SF 3749M 6M
Pfizer PFE:US $ 8671M 1339M
Regeneron Pharmaceuticals REGN:US $ 297.1M 107.8M
Sarepta Therapeutics SRPT:US $ 37.8M 6.35M
Vertex Pharmaceuticals VRTX:US $ 261.8M 16M